StockPulse is a software subscription service that translates and summarizes U.S. stock filings and news into alerts. It is not an investment advisory, brokerage, or discretionary management service.

All information provided (filing summaries, price data, keywords, etc.) is processed from public sources for reference only and is not a recommendation to buy or sell any security. Investment decisions and their outcomes are the sole responsibility of the user.

노마드랩 주식회사 · 대표 황승준 · 사업자등록번호 588-81-01342

부산광역시 해운대구 센텀중앙로 55, 9층 7호(우동)

통신판매업 제2026-부산해운대-0983호 · 문의  

고객문의 070-4268-1176

App Store▶ Google Play
GuideFAQWeeklyTerms of ServicePrivacy PolicyPayment & Refund Policy

StockPulse · 스탁펄스(스톡펄스) — 미국주식 공시·뉴스 실시간 알림

© 2026 노마드랩 주식회사. All rights reserved.

StockPulseStockPulseFeedReportMacro·SectorsCommunityAlertsMy
Theme
FeedReportMacro·SectorsCommunityAlertsMy
IPHAInnate Pharma SA
stockpulse.co.kr
Nasdaq
$1.50▲ 1.01%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $140.6MShares out 93.7M sh
At a glance🔒 At-a-glance is MAX onlySee plans

Chart

Filings & news by date

Hover (PC) or tap (mobile) a candle to see that day only

🔒 Members only
Live tape🔒 Live tape is MAX onlySee plans

Filings

11
  • 4d agoPre-market26.10.21 19:08
    6-KKey event#●●●#●●●

    Innate Pharma SA

    Innate Pharma announced its participation in the upcoming Stifel Healthcare Conference and Jefferies Global Healthcare Conference in November 2026. The company's executive team will hold a fireside chat at the Stifel conference on November 10, 2026.…more

    $1.50+1.01%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    View filingShare
  • 5d agoPre-market26.10.20 19:09
    6-KKey event

    Innate Pharma SA

    Innate Pharma will hold a conference call on November 5, 2026, at 8:00 a.m. ET to provide a business and financial update for the third quarter of 2026. The company's executive leadership, including CEO Jonathan Dickinson, will participate in the event to discuss the latest business developments.…more

    $1.50+1.01%vs prev close
    View filingShare
  • 9.17Pre-market26.09.17 19:33
    6-KKey event

    Innate Pharma SA

    Innate Pharma has secured a $75 million upfront payment from its strategic partnership with Sobi and completed a €30 million capital increase, extending its cash runway through Q1 2028. For the first half of 2026, the company reported revenue of €5.66 million and a net loss of €19.62 million, while continuing to advance key programs including the TELLOMAK-3 Phase 3 trial and IPH4502.…more

    $1.50+1.01%vs prev close
    View filingShare

10 more filings

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →

News

GlobeNewswire
  • 9.17Pre-market26.09.17 20:11
    #●●●

    Earnings Scheduled For September 17, 2026

    Several companies including 111, Innate Pharma, and Upexi are scheduled to report their quarterly earnings. Investors should note that Innate Pharma and Upexi are projected to report quarterly losses.…more

    $1.50+1.01%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    ShareBenzinga
  • 9.17Overnight26.09.17 14:12

    ●●●●●●●● ●●●●● ●●●●●●

    Innate Pharma reported a loss per share of $0.24 and revenue of $6.583 million, both missing analyst expectations. Despite a slight year-over-year revenue increase, the wider-than-expected losses weigh on the company's financial performance.…more

    $1.50+1.01%vs prev close
    ShareBenzinga

1 more news items

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →